Does Rallies show 13F holders for KPRX?

Yes. Rallies tracks hedge fund and 13F ownership data for KPRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is KPRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KPRX. It does not provide personalized investment advice.

KPRX (Kiora Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Kiora Pharmaceuticals, Inc. Common Stock (KPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, KPRX trades at $2.64 with a market cap of $11.12M and a P/E ratio of -1.01. KPRX moved +0.40% today. Year to date, KPRX is +25.71%; over the trailing twelve months it is -15.33%. Its 52-week range spans $1.76 to $4.18. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces KPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns KPRX stock?

Hedge funds tracked by Rallies that own KPRX include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Kiora Pharmaceuticals, Inc. Common Stock.

KPRX Key Metrics

Key financial metrics for KPRX
Metric	Value
Price	$2.64
Market Cap	$11.12M
P/E Ratio	-1.01
EPS	$-2.60
Dividend Yield	0.00%
52-Week High	$4.18
52-Week Low	$1.76
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-10.84M
Gross Margin	0.00%

Top Hedge Funds Holding KPRX

Renaissance Technologies holds 16.66K shares of KPRX, changed -10.94% as of Mar 31, 2024.
Citadel Advisors holds 10.11K shares of KPRX, changed -89.08% as of Sep 30, 2024.

Latest KPRX News

Kiora Reports No Serious Adverse Events in Phase 1 KIO-301 Study, Initiates Phase 2 Trial — Apr 14, 2026
Kiora Pharmaceuticals Secures $24 Million Private Placement Led by Perceptive Advisors — Apr 7, 2026
Kiora Pharmaceuticals CDO to Resign April 17; Phase 2 100µg Cohort Initiated — Apr 2, 2026
Kiora Advances Two Phase II Trials, Secures $110M Asia Option and $17.1M Cash — Mar 25, 2026

Recent KPRX Insider Trades

Stengone Carmine N. bought 1.25K (~$4.60K) on Sep 11, 2024.
Shapiro Aron bought 3.00K (~$10.80K) on Sep 10, 2024.
Walters-Hoffert Lisa bought 1.25K (~$4.83K) on Aug 19, 2024.

KPRX Analyst Consensus

1 analysts cover KPRX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about KPRX

Who owns KPRX stock?: Hedge funds tracked by Rallies that own KPRX include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Kiora Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for KPRX?: Yes. Rallies tracks hedge fund and 13F ownership data for KPRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is KPRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KPRX. It does not provide personalized investment advice.